Julieann Sludden

1.5k total citations
19 papers, 1.2k citations indexed

About

Julieann Sludden is a scholar working on Molecular Biology, Oncology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Julieann Sludden has authored 19 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 8 papers in Oncology and 4 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Julieann Sludden's work include Cancer therapeutics and mechanisms (5 papers), Acute Lymphoblastic Leukemia research (4 papers) and DNA Repair Mechanisms (3 papers). Julieann Sludden is often cited by papers focused on Cancer therapeutics and mechanisms (5 papers), Acute Lymphoblastic Leukemia research (4 papers) and DNA Repair Mechanisms (3 papers). Julieann Sludden collaborates with scholars based in United Kingdom, United States and Australia. Julieann Sludden's co-authors include Robert Brown, Stanley B. Kaye, Gordon Strathdee, Jane A. Plumb, Alan V. Boddy, David Jamieson, Alexander I. Gray, Ijeoma F. Uchegbu, Ruth Plummer and Andreas G. Schätzlein and has published in prestigious journals such as Clinical Cancer Research, British Journal of Cancer and European Journal of Cancer.

In The Last Decade

Julieann Sludden

19 papers receiving 1.2k citations

Peers

Countries citing papers authored by Julieann Sludden

Since Specialization

Citations

This map shows the geographic impact of Julieann Sludden's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julieann Sludden with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julieann Sludden more than expected).

Fields of papers citing papers by Julieann Sludden

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Julieann Sludden. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julieann Sludden. The network helps show where Julieann Sludden may publish in the future.

Co-authorship network of co-authors of Julieann Sludden

This figure shows the co-authorship network connecting the top 25 collaborators of Julieann Sludden. A scholar is included among the top collaborators of Julieann Sludden based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Julieann Sludden. Julieann Sludden is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work	Indexed citations
1	A Phase 1/2A trial of idroxioleic acid: first-in-class sphingolipid regulator and glioma cell autophagy inducer with antitumor activity in refractory glioma 2023 ·British Journal of Cancer ·Juanita Lopez, Julia Lai‐Kwon, R. Molife, Liam Welsh, Nina Tunariu, Desamparados Roda, (unknown), Victoria Lladó, Adrián G. McNicholl, Catalina Ana Rosselló, Richard Taylor, Analía Azaro, Jordi Rodón, Julieann Sludden, Gareth J. Veal, Ruth Plummer, Ander Urruticoechea, (unknown), (unknown), Pablo V. Escribá	10
2	Pharmacokinetics and Pharmacogenetics of Cyclophosphamide in a Neonate and Infant Childhood Cancer Patient Population 2021 ·Pharmaceuticals ·S. Barnett, Julie Errington, Julieann Sludden, David Jamieson, Vianney Poinsignon, Angélo Paci, Gareth J. Veal	19
3	Development and Validation of A LC–MS/MS Method for The Quantification of The Checkpoint Kinase 1 Inhibitor Sra737 in Human Plasma 2017 ·Bioanalysis ·(unknown), Philip Berry, Julieann Sludden, Florence I. Raynaud, Udai Banerji, Paul S. Jones, David Edwards, Gareth J. Veal	4
4	Pharmacogenetic association of MBL2 and CD95 polymorphisms with grade 3 infection following adjuvant therapy for breast cancer with doxorubicin and cyclophosphamide 2016 ·European Journal of Cancer ·David Jamieson, Nicola J. Sunter, (unknown), (unknown), Nicola Cresti, (unknown), Julieann Sludden, (unknown), James M. Allan, Mark Verrill, Alan V. Boddy	6
5	Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer 2016 ·British Journal of Cancer ·Yvette Drew, Jonathan A. Ledermann, Geoff Hall, Daniel Rea, Rosalind Glasspool, Martin Highley, Gordon C. Jayson, Julieann Sludden, J. C. Murray, David Jamieson, Sarah Halford, Gary D Acton, (unknown), Raffaella Mangano, Alan V. Boddy, Nicola J. Curtin, Ruth Plummer	126
6	Cyclophosphamide pharmacokinetics and pharmacogenetics in children with B-cell non-Hodgkin's lymphoma 2016 ·European Journal of Cancer ·Gareth J. Veal, Michael Cole, Girish Chinnaswamy, Julieann Sludden, David Jamieson, Julie Errington, (unknown), Christopher Hill, Thomas C. Chamberlain, Alan V. Boddy	50
7	Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System 2015 ·Molecular Cancer Therapeutics ·Karen E. Parrish, Ling Cen, J. C. Murray, David Calligaris, Sani H. Kizilbash, Rajendar K. Mittapalli, Brett L. Carlson, Mark A. Schroeder, Julieann Sludden, Alan V. Boddy, Nathalie Y.R. Agar, Nicola J. Curtin, William F. Elmquist, Jann N. Sarkaria	66
8	Two minor NQO1 and NQO2 alleles predict poor response of breast cancer patients to adjuvant doxorubicin and cyclophosphamide therapy 2011 ·Pharmacogenetics and Genomics ·David Jamieson, Nicola Cresti, (unknown), Julieann Sludden, (unknown), (unknown), (unknown), Emily Mould, Mark Verrill, Felicity E. B. May, Alan V. Boddy	30
9	Phase I Study of MG98, an Oligonucleotide Antisense Inhibitor of Human DNA Methyltransferase 1, Given as a 7-Day Infusion in Patients with Advanced Solid Tumors 2009 ·Clinical Cancer Research ·Ruth Plummer, Laura Vidal, Martin Griffin, (unknown), Johann S. de Bono, Sally A. Coulthard, Julieann Sludden, Lillian L. Siu, Eric X. Chen, Amit M. Oza, Gregory K. Reid, (unknown), Jeffrey M. Besterman, (unknown), Ian Judson, Hilary Calvert, Alan V. Boddy	97
10	Pharmacokinetic Investigation of Imatinib Using Accelerator Mass Spectrometry in Patients with Chronic Myeloid Leukemia 2007 ·Clinical Cancer Research ·Alan V. Boddy, Julieann Sludden, Melanie Griffin, Colin Garner, (unknown), (unknown), Catherine Dutreix, David R. Newell, Stephen G. O’Brien	22
11	A Phase I and Pharmacokinetic Study of Paclitaxel Poliglumex (XYOTAX), Investigating Both 3-Weekly and 2-Weekly Schedules 2005 ·Clinical Cancer Research ·Alan V. Boddy, E. Ruth Plummer, (unknown), Julieann Sludden, Melanie Griffin, L Robson, James T. Cassidy, Donald Bissett, A. Bernareggi, Mark Verrill, A H Calvert	84
12	Determination of anti-cancer drug actinomycin D in human plasma by liquid chromatography–mass spectrometry 2003 ·Journal of Chromatography B ·Gareth J. Veal, Julie Errington, Julieann Sludden, (unknown), L Price, (unknown), Juliet Hale, Andrew D.J. Pearson, Alan V. Boddy	19
13	Pharmacological study of paclitaxel duration of infusion combined with GFR-based carboplatin in the treatment of ovarian cancer 2001 ·Cancer Chemotherapy and Pharmacology ·Huw D. Thomas, (unknown), James G. Wright, Ruth Plummer, Martin Highley, Hilary Calvert, Martin Griffin, Alan V. Boddy, Julieann Sludden	5
14	Evaluation of dihydropyrimidine dehydrogenase activity in South‐west Asian, Kenyan and Ghanaian populations 2000 ·British Journal of Clinical Pharmacology ·(unknown), Julieann Sludden, Margaret‐Mary Ameyaw, Jessie Githanga, Anne Indalo, David Ofori‐Adjei, (unknown)	26
15	Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. 2000 ·PubMed ·Jane A. Plumb, Gordon Strathdee, Julieann Sludden, Stanley B. Kaye, Robert Brown	390
16	Polymeric Chitosan-based Vesicles for Drug Delivery 1998 ·Journal of Pharmacy and Pharmacology ·Ijeoma F. Uchegbu, Andreas G. Schätzlein, Laurence Tetley, Alexander I. Gray, Julieann Sludden, (unknown), (unknown)	96
17	Liver Dihydropyrimidine Dehydrogenase Activity in Human, Cynomolgus Monkey, Rhesus Monkey, Dog, Rat and Mouse 1998 ·Pharmacology ·Julieann Sludden, (unknown), Mark VandenBranden, Steven Wrighton, Howard L. McLeod	9
18	Dihydropyrimidine dehydrogenase pharmacogenetics in Caucasian subjects 1998 ·British Journal of Clinical Pharmacology ·Susan A. Ridge, Julieann Sludden, Oliver E. Brown, (unknown), Xiaoxiong Wei, Andrea Sapone, Pedro M. Fernández‐Salguero, Frank J. Gonzalez, P. Vreken, André B. P. Kuilenburg, Albert H. Gennip, Howard L. McLeod	105
19	Ethnic differences in catechol O-methyltransferase pharmacogenetics 1998 ·Pharmacogenetics ·Howard L. McLeod, (unknown), (unknown), Anne Indalo, (unknown), (unknown), Ismo Ulmanen, Julieann Sludden	22

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact